Business Wire

Pharmanovia Enters In-Licensing Agreement With Axsome Therapeutics to Market and Further Develop Sunosi® (solriamfetol), a First-In-Class Treatment for Excessive Daytime Sleepiness (EDS) in People With Narcolepsy and Obstructive Sleep Apnoea

Share

FOR TRADE AND BUSINESS MEDIA ONLY

Pharmanovia, a global pharmaceutical company that revitalises, extends and expands the lifecycle of already established medicines, has today announced the expansion of its neurology portfolio through a new licensing agreement with US-based biopharmaceutical company, Axsome Therapeutics, Inc.

The agreement gives Pharmanovia the exclusive marketing rights to Sunosi® (solriamfetol), a first in class medicine used to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnoea (OSA)1, in Europe and MENA regions. Pharmanovia will continue researching solriamfetol’s potential in children. A pivotal Phase III study and longer-term extension study, exploring the safety and effectiveness of solriamfetol in children with narcolepsy, will be initiated by Pharmanovia, with the aim of bringing this breakthrough therapy to young people affected by this debilitating disease. The agreement also allows Pharmanovia to explore solriamfetol’s potential in other neurological conditions, such as attention deficit hyperactivity disorder (ADHD).

Global estimates using five or more events per hour suggest rates of 936 million people worldwide with mild to severe OSA, and 425 million people worldwide with moderate to severe OSA, between the ages of 30 and 69 years of age.2 EDS can have a huge impact on an individual’s quality of life and ability to function day to day, with common signs and symptoms including brain fog, frequent tiredness and unrefreshing sleep.

Pharmanovia CEO, James Burt commented; “We are delighted to have been recognised by Axsome as the right overseas partner both for the expansion in Europe and in bringing this important medicine to MENA. In addition to our focus on lifecycle management of iconic brands, a key pillar of our strategy is to utilise our extensive technical and commercial platform to bring novel, complementary medicines to patients in the therapeutic settings we support. In-licensing a novel, first-in-class neurological medicine is a great demonstration of delivering on this strategy.

“We’re especially excited to initiate the paediatric trials in narcolepsy. Clinical research in children is inherently more sensitive and, as a result, there are countless medical interventions with the potential to bring life-changing benefits to young people that have simply not been tested and, therefore, cannot currently be used.”

Dr. Herriot Tabuteau, CEO of Axsome Therapeutics, added: “Solriamfetol is an important medicine with demonstrated clinically meaningful efficacy and a unique mechanism of action. This partnership builds on Pharmanovia’s established neurology footprint across Europe and MENA and facilitates solriamfetol reaching as many patients that could benefit from it as possible. Partnering with Pharmanovia is a natural choice for us, given their alignment with us on the value that solriamfetol presents and their plans to expand access.”

-Ends-

Notes to editors

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences.

With a diverse and growing team in over 140 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, it is transforming the approach to treating CNS conditions. Axsome is committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians.

About Sunosi® (solriamfetol)

Solriamfetol is the first and only approved, dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with EDS associated with narcolepsy or OSA.

In patients with OSA, both in patients who were adherent to their primary OSA treatment and those who were non-adherent, solriamfetol was shown to:3

  • Increase wakefulness in a dose dependent fashion at Week 12, as measured by the MWT
  • Decrease sleepiness in a dose dependent fashion at Week 12, as measured by the ESS
  • Increase patient reports of feeling better at Week 12, as measured by the PGI-C

Similarly in patients with narcolepsy, solriamfetol was shown to:4

  • Significantly improve wakefulness as early as week 1, which was maintained through 12 weeks
  • At week 12, significantly increased wakefulness as early as 1 hour; with effects maintained through 9 hours post-dose

References

  1. https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi - Last accessed 21.2.23
  2. PLOS One, 2021, Mandereau-Bruno et al., Obstructive sleep apnea: A sharp increase in the prevalence of patients treated with nasal CPAP over the last decade in France, accessed here: https://uk01.z.antigena.com/l/Cd3ygbEm88lHtCKPjqjPtRfBnH~JIn_BbvAm07Uwym~AKBTOm3hRsjrPhYpYM0phFCee4qPFzoVjIVs90kIsPzSHJ9uftESuHSV3aCzLe2tAH3ffv7tNPypv-58xEo44TdGJzsbyyOVIbGe_rEE18gNNe6_Ey_w~TVB21_BXvr4_2guD6e8ZXw7W24_XBjnMH__
    UpToDate, 2023, Kline, Clinical presentation and diagnosis of obstructive sleep apnea in adults, accessed here: https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-obstructive-sleep-apnea-in-adults#:~:text=Global%20estimates%20using%20five%20or,OSA%20also%20varies%20by%20race
    Eurostat, accessed here: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_and_population_change_statistics
    https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-obstructive-sleep-apnea-in-adults/print#:~:text=Global%20estimates%20using%20five%20or,OSA%20also%20varies%20by%20race.
  3. Schweitzer, PK, et al. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment. Chest. 2021; 160(1):307-318
  4. Thorpy MJ, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019; 85(3):359-370. doi: 10.1002/ana.25423

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ Alison.dyson@pharmanovia.com
Or pharmanovia@67health.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PAN Finance Names Libertex ‘Global CFD Broker of the Year’29.3.2024 08:25:00 EET | Press release

As the first quarter of 2024 draws to a close, Libertex is thrilled to announce its first accolade of the new year! The established global financial publication PAN Finance has determined Libertex to be the ‘CFD Broker of the Year – Global 2024’ following a rigorous evaluation process conducted by the publication's highly experienced editorial and research teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328235325/en/ (Graphic: Libertex) PAN Finance is a trusted source of global financial intelligence with an impressively wide readership across 150 countries. Its ecosystem includes a quarterly magazine, special reports, a news website, and various social media channels. As an organisation, PAN Finance is committed to providing concise, intelligent, and up-to-date news for a worldwide readership of specialists spanning the entire finance industry. The company's awards programme aims to serve as a true indicator of exc

Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.29.3.2024 04:39:00 EET | Press release

Midea Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328526418/en/ Background: Midea Group, a leading global technology group, recently released its 2023 Environmental, Social, and Governance (ESG) Report with ambitious sustainable development goals set for 2030. They include achieving over 500 megawatts of photovoltaic power generation, reducing greenhouse gas emission intensity (scopes 1 and 2) by 0.040, secure Energy Management System Certification for 50 factories, and achieve 100% carbon footprint accounting for major categories of smart home appliances. This is aligned with the Sustainable Development Report Standards of the Global Report Standards of the Global Reporting Initiative (GRI). The new report and campaign focuses on four dimensions: Protect the Blue Planet, Build a Harmonious Community, Practice 'Bring Great Innovations to Life', and Jointly Create the Prosperous Ecology. The campaign: Midea’s ESG

DC Secretary Announces Annual Determinations Committees Outcome28.3.2024 23:14:00 EET | Press release

DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 27, 2024. Voting Dealers (for all regions): Voting Non-Dealers (for all regions): Bank of America N.A. Citadel LLC Barclays Bank plc Elliott Management Corporation BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Voting Dealer for the Americas, EMEA, AEJ, and Japan Determination Committees: Mizuho Securities Co., Ltd. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommittees.org/. View source version on businesswire.com: https://www.businesswire.com/news/home/20240328441002/en/ Contact information Press Inquiries: Orlando Figueroa orlando.figueroa@citadelspv.com

Faster Recoveries, Improved Security: HTEC and G2 Risk Solutions Join Forces to Advance Bankruptcy Management28.3.2024 19:02:00 EET | Press release

HTEC, a global digital consulting, software engineering, and product development company, is announcing a strategic collaboration with G2 Risk Solutions (G2RS), the preeminent provider of end-to-end bankruptcy technology solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328622816/en/ HTEC & G2 Risk Solutions Partnership (Photo: Business Wire) Under the agreement, G2RS will engage HTEC to incorporate its leading-edge technology into G2RS’ premier bankruptcy management platform. As the creators of the most comprehensive national bankruptcy database and the first bankruptcy management portal, G2RS is an industry pioneer. By adding HTEC’s premium engineering to the G2RS technology stack, G2RS will offer new and innovative functionalities to help clients expedite financial recoveries, increase data protection, and reduce operational inefficiencies in the bankruptcy management life cycle. “We are thrilled to be a part o

LambdaTest Launches The Phoenix Project, an Employee Resource Group for Women28.3.2024 18:00:00 EET | Press release

LambdaTest, a leading cloud-based unified testing platform, announced the launch of The Phoenix Project, an Employee Resource Group (ERG) dedicated to supporting and promoting the success of its female employees. “LambdaTest is committed to fostering a diverse, inclusive, and equitable workplace where all employees feel valued and empowered to reach their full potential,” said Chandini Chopra, VP of People and Culture at LambdaTest. “The Phoenix Project is a critical step towards achieving this goal by providing a platform for professional development, networking, and mentorship, especially for our women employees.” The Phoenix Project Aims To: Offer professional development workshops, networking opportunities, and dedicated time off for women to participate in ERG initiatives. Provide mentorship programs connecting senior female employees with mentees. Promote leadership development among women within the company. Create a sense of community for women in the workplace. Leadership and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye